Market Access

With ustekinumab biosimilars set to launch in Europe imminently and in the US early next year, the off-patent industry may be wondering whether it will be in for a rerun of its experiences with competition on Humira – or whether the landscape has changed sufficiently to allow for different pricing and uptake trends. 

Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.

Payers are restricting access to obesity drugs due to huge patient numbers and a wave of innovation in other areas

Medtech companies have typically seen a “mixed picture of growth” in China in the past year or two, but it is a market that requires ongoing commitment, a panel of experts argued at the MedTech Forum 2024.

If artificial intelligence and connected care are the answer to growing demand for care from health systems under pressure, why is the question apparently falling on deaf ears? ZS principal Brian Chapman sums up the state of play.

A GenAI copilot for biopharma regulatory requirements could yield significant returns.

Record attendance at the 2024 MedTech Forum in Vienna heard industry leaders voice optimism grounded in realism about future developments for Europe’s medtech industry, markets and delivery of care to patients. In Vivo filtered out 16 trends to watch.

Proportionately regulating highly adaptive AI as a medical device can be done with predetermined change control plans. The US, UK and Canada are advancing the concept, as Ropes & Gray and the US FDA explained.

Medical devices selected for use in the Guangdong-Hong Kong-Macao Greater Bay Area may potentially be fast-tracked for adoption across mainland China, according to a new industry white paper.

Astellas Pharma’s chief commercial officer discusses the biopharma industry’s responsibility to drive change in health care.

With the passage of the Inflation Reduction Act, many have questioned whether Medicare price negotiations will stifle small molecule innovation.

The FTC is intensifying its crackdown on pharmaceutical companies' misuse of patent listings as industry seeks clearer guidelines.

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve access to lifesaving therapies. Payers and politicians must be persuaded to loosen their purse strings – and open their minds.

Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social care, in conversation with In Vivo.

Industry is researching alternatives to PVC for medicines packaging, but content integrity must remain paramount, says Circpack consultancy’s Filipe Viera de Castro, who puts the case for companies to contribute to waste management costs.

ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.